Evidence map›Paper›PMID 35734924›Full record

Trial reportHaematologica2022

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.

Rami S Komrokji, Hetty E Carraway, Ulrich Germing, Martin Wermke, Amer M Zeidan, Eric Fu, Björn Rüter, Ute Burkard, Annika Osswald, James M Foran

Open access · goldAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 3 countries.

Rami S KomrokjiMalignant Hematology Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Rami.Komrokji@moffitt.org.
Hetty E CarrawayLeukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Ulrich GermingDepartment of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University Dusseldorf, Universitätsklinikum, Dusseldorf.
Martin WermkeNCT/UCC-ECTU, Medical Faculty Carl Gustav Carus, Technical University, Dresden.
Amer M ZeidanDepartment of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT.
Eric FuBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Björn RüterBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.
Ute BurkardBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.
Annika OsswaldBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.
James M ForanDepartment of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
Boehringer Ingelheim (India) · INBoehringer Ingelheim (United States) · USCleveland Clinic · USDüsseldorf University Hospital · DEMayo Clinic in Florida · USMoffitt Cancer Center · USUniversity Hospital Carl Gustav Carus · DEYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic SyndromesAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugHumansImmunoglobulin Fc FragmentsTreatment OutcomeAntibodies, Monoclonal, HumanizedBI 836858Immunoglobulin Fc Fragments

Identifiers

PMID35734924
PMCPMC9614517
OpenAlexW4283323477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.